TOKYO – Japanese authorities are stepping up their push to become more transparent by working with foreign companies in the health care product market.
- 'Bromo' seltzer: Merck's Oncoethix buyout puts renewed fizz into epigenetic strategy
- Tetraphase on fire with positive phase III data for antibiotic eravacycline
- Bad news, good news: Costs are up, but so are returns, says Deloitte
- First of the glimins, Poxel diabetes drug hits phase IIb endpoint
- Myriad sequel: DNA-based synthetic primers also ...
- Hutchison-discovered fruquintinib moves into phase III testing in metastatic CRC
- Lilly trade secrets case dismissed for lack of evidence; Chinese-born employees released
- Shanghai's Generon hits endpoint in global phase II neutropenia trial
- Immune modulator for MS improves acute stroke outcomes
- Post Abe re-election, new policies set to help h...
With the relatively recent arrival of new oral anticoagulants (NOACs) vying to displace warfarin with the promise of fewer side effects, easier dosing and less need for regular monitoring, patients and their doctors have gained valuable new tools to reduce the risks of blood clots.
Bisphosphonates have been used since the early 1990s in two indications. They are most famous as osteoporosis drugs, where even off-patent, Fosamax (alendronate sodium, Merck & Co. Inc.) only one of several bisphosphonates raked in more than $700 million in sales in 2013, according to Thomson Reuters Cortellis.
They are also used in cancer "primarily to prevent bone metastases and their consequences, but never for the cancer itself," Mone Zaidi told BioWorld Today.READ MORE »
- Resistance findings may lead to new antibiotics »
- Dengue antibody recognizes 2 proteins, protects against all 4 strains »
- Immune modulator for MS improves acute stroke outcomes »
- Secretory structure clues may lead to antibiotics aimed at biofilms »
- Antibody mix protects against lethal hantavirus »
- Gene therapy cures mice of cardiomyopathy »
- Immune cell discovery may lead to new MS treatments »
- Multiple studies report progress in immuno-oncology »
- Spaghetti junction controls molecular traffic to the nucleus »
- Old dogs and new tricks: The real-world consequences of excluding older adults from drug trialsDecember 10, 2014 | 8:14 PM | Posted by: Marie Powers
- Shoppers, start your engines: BioWorld’s 8th Annual Gift GuideDecember 01, 2014 | 6:12 PM | Posted by: Marie Powers
- Death and taxes: Is the corporate tax rate killing the U.S. economy?October 24, 2014 | 2:54 PM | Posted by: Ann Duncan
- A shot in the dark? ‘Flu’ Manchu-type fears of evil pharma, plus frets over strains and safety, keep too many away from vaccineOctober 07, 2014 | 10:22 PM | Posted by: Randy Osborne
- Emerging biosimilar market knows no parallelSeptember 29, 2014 | 6:15 PM | Posted by: Mari Serebrov
Partners in Focus
Cast Your Vote
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter